Analyse Alpha Teknova, Inc. (TKNO) — Kairos Score 70/100

À propos de Alpha Teknova, Inc.

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Alpha Teknova, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur TKNO dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur TKNO.

• Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
• All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.